Serveur d'exploration sur la grippe en France

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population-based study in France.

Identifieur interne : 000191 ( Main/Exploration ); précédent : 000190; suivant : 000192

Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population-based study in France.

Auteurs : Guillaume Moulis [France] ; Maryse Lapeyre-Mestre ; Matthieu Mahévas ; Jean-Louis Montastruc ; Laurent Sailler

Source :

RBID : pubmed:25557586

Descripteurs français

English descriptors

Abstract

International guidelines on immune thrombocytopenia (ITP) management recommend vaccination against Streptococcus pneumoniae (S.p.), Haemophilus influenza b (Hib) and Neisseiria meningitidis (N.m.) before splenectomy. French guidelines also recommend these vaccinations before rituximab. The aim of this study was to assess the application of these recommendations. The French Adult ITP: a French pHarmacoepidemiological study (FAITH, n°ENCEPP 4574) is aimed at following in the French national health insurance system database (SNIIRAM) the cohort of all incident and persistent or chronic primary ITP adults treated in France. We assessed vaccine exposure in the 1,106 patients who entered the FAITH cohort between 2009 and 2011. Vaccination was said "recommended" if performed at least 2 weeks before rituximab or splenectomy accordingly with French guidelines. Among the 423 non-splenectomized patients exposed to rituximab, vaccination rates against S.p., Hib and N.m. were respectively 32.4%, 18.9%, and 3.8%. It was recommended in 12.8%, 6.6%, and 1.2% of the patients, respectively. Among the 178 splenectomized patients, vaccination rates were 70.2%, 47.0%, and 11.9%, respectively (recommended: 60.1%, 35.7%, and 9.5%). Among the splenectomized patients previously exposed to rituximab (n = 67), 53.3% of the vaccinations occurred during the semester following a rituximab infusion that is during the maximal B-cell depletion period. In multivariate analyses, a disease duration exceeding 3 months was the sole factor associated to recommended vaccination in rituximab-treated patients as well as in splenectomized patients. This study stresses the need of better and earlier vaccination of ITP patients.

DOI: 10.1002/ajh.23930
PubMed: 25557586


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population-based study in France.</title>
<author>
<name sortKey="Moulis, Guillaume" sort="Moulis, Guillaume" uniqKey="Moulis G" first="Guillaume" last="Moulis">Guillaume Moulis</name>
<affiliation wicri:level="3">
<nlm:affiliation>Service De Médecine Interne, CHU De Toulouse, Toulouse, F-31000, France; Inserm, UMR1027, Toulouse, F-31000 France, Université De Toulouse III, UMR1027, Toulouse, F-31000, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service De Médecine Interne, CHU De Toulouse, Toulouse, F-31000, France; Inserm, UMR1027, Toulouse, F-31000 France, Université De Toulouse III, UMR1027, Toulouse, F-31000</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Occitanie (région administrative)</region>
<region type="old region" nuts="2">Midi-Pyrénées</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Lapeyre Mestre, Maryse" sort="Lapeyre Mestre, Maryse" uniqKey="Lapeyre Mestre M" first="Maryse" last="Lapeyre-Mestre">Maryse Lapeyre-Mestre</name>
</author>
<author>
<name sortKey="Mahevas, Matthieu" sort="Mahevas, Matthieu" uniqKey="Mahevas M" first="Matthieu" last="Mahévas">Matthieu Mahévas</name>
</author>
<author>
<name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name>
</author>
<author>
<name sortKey="Sailler, Laurent" sort="Sailler, Laurent" uniqKey="Sailler L" first="Laurent" last="Sailler">Laurent Sailler</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:25557586</idno>
<idno type="pmid">25557586</idno>
<idno type="doi">10.1002/ajh.23930</idno>
<idno type="wicri:Area/Main/Corpus">000204</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000204</idno>
<idno type="wicri:Area/Main/Curation">000204</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000204</idno>
<idno type="wicri:Area/Main/Exploration">000204</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population-based study in France.</title>
<author>
<name sortKey="Moulis, Guillaume" sort="Moulis, Guillaume" uniqKey="Moulis G" first="Guillaume" last="Moulis">Guillaume Moulis</name>
<affiliation wicri:level="3">
<nlm:affiliation>Service De Médecine Interne, CHU De Toulouse, Toulouse, F-31000, France; Inserm, UMR1027, Toulouse, F-31000 France, Université De Toulouse III, UMR1027, Toulouse, F-31000, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service De Médecine Interne, CHU De Toulouse, Toulouse, F-31000, France; Inserm, UMR1027, Toulouse, F-31000 France, Université De Toulouse III, UMR1027, Toulouse, F-31000</wicri:regionArea>
<placeName>
<region type="region" nuts="2">Occitanie (région administrative)</region>
<region type="old region" nuts="2">Midi-Pyrénées</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Lapeyre Mestre, Maryse" sort="Lapeyre Mestre, Maryse" uniqKey="Lapeyre Mestre M" first="Maryse" last="Lapeyre-Mestre">Maryse Lapeyre-Mestre</name>
</author>
<author>
<name sortKey="Mahevas, Matthieu" sort="Mahevas, Matthieu" uniqKey="Mahevas M" first="Matthieu" last="Mahévas">Matthieu Mahévas</name>
</author>
<author>
<name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name>
</author>
<author>
<name sortKey="Sailler, Laurent" sort="Sailler, Laurent" uniqKey="Sailler L" first="Laurent" last="Sailler">Laurent Sailler</name>
</author>
</analytic>
<series>
<title level="j">American journal of hematology</title>
<idno type="eISSN">1096-8652</idno>
<imprint>
<date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Antibodies, Monoclonal, Murine-Derived (administration & dosage)</term>
<term>Antibodies, Monoclonal, Murine-Derived (adverse effects)</term>
<term>Antibodies, Monoclonal, Murine-Derived (therapeutic use)</term>
<term>Bacterial Infections (epidemiology)</term>
<term>Bacterial Infections (immunology)</term>
<term>Bacterial Infections (microbiology)</term>
<term>Bacterial Infections (prevention & control)</term>
<term>Bacterial Vaccines (administration & dosage)</term>
<term>Cohort Studies (MeSH)</term>
<term>Drug Administration Schedule (MeSH)</term>
<term>Epidemiologic Research Design (MeSH)</term>
<term>Female (MeSH)</term>
<term>France (epidemiology)</term>
<term>Humans (MeSH)</term>
<term>Immunologic Factors (administration & dosage)</term>
<term>Immunologic Factors (adverse effects)</term>
<term>Immunologic Factors (therapeutic use)</term>
<term>Logistic Models (MeSH)</term>
<term>Male (MeSH)</term>
<term>Practice Guidelines as Topic (MeSH)</term>
<term>Purpura, Thrombocytopenic, Idiopathic (drug therapy)</term>
<term>Purpura, Thrombocytopenic, Idiopathic (epidemiology)</term>
<term>Purpura, Thrombocytopenic, Idiopathic (immunology)</term>
<term>Purpura, Thrombocytopenic, Idiopathic (therapy)</term>
<term>Rituximab (MeSH)</term>
<term>Splenectomy (MeSH)</term>
<term>Vaccination (statistics & numerical data)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Anticorps monoclonaux d'origine murine (administration et posologie)</term>
<term>Anticorps monoclonaux d'origine murine (effets indésirables)</term>
<term>Anticorps monoclonaux d'origine murine (usage thérapeutique)</term>
<term>Calendrier d'administration des médicaments (MeSH)</term>
<term>Facteurs immunologiques (administration et posologie)</term>
<term>Facteurs immunologiques (effets indésirables)</term>
<term>Facteurs immunologiques (usage thérapeutique)</term>
<term>Femelle (MeSH)</term>
<term>France (épidémiologie)</term>
<term>Guides de bonnes pratiques cliniques comme sujet (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Infections bactériennes (immunologie)</term>
<term>Infections bactériennes (microbiologie)</term>
<term>Infections bactériennes (prévention et contrôle)</term>
<term>Infections bactériennes (épidémiologie)</term>
<term>Modèles logistiques (MeSH)</term>
<term>Mâle (MeSH)</term>
<term>Méthodologie en recherche épidémiologique (MeSH)</term>
<term>Purpura thrombopénique idiopathique (immunologie)</term>
<term>Purpura thrombopénique idiopathique (thérapie)</term>
<term>Purpura thrombopénique idiopathique (traitement médicamenteux)</term>
<term>Purpura thrombopénique idiopathique (épidémiologie)</term>
<term>Rituximab (MeSH)</term>
<term>Splénectomie (MeSH)</term>
<term>Vaccination (statistiques et données numériques)</term>
<term>Vaccins antibactériens (administration et posologie)</term>
<term>Études de cohortes (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en">
<term>Antibodies, Monoclonal, Murine-Derived</term>
<term>Bacterial Vaccines</term>
<term>Immunologic Factors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en">
<term>Antibodies, Monoclonal, Murine-Derived</term>
<term>Immunologic Factors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Antibodies, Monoclonal, Murine-Derived</term>
<term>Immunologic Factors</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en">
<term>France</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr">
<term>Anticorps monoclonaux d'origine murine</term>
<term>Facteurs immunologiques</term>
<term>Vaccins antibactériens</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Purpura, Thrombocytopenic, Idiopathic</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr">
<term>Anticorps monoclonaux d'origine murine</term>
<term>Facteurs immunologiques</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en">
<term>Bacterial Infections</term>
<term>Purpura, Thrombocytopenic, Idiopathic</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr">
<term>Infections bactériennes</term>
<term>Purpura thrombopénique idiopathique</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en">
<term>Bacterial Infections</term>
<term>Purpura, Thrombocytopenic, Idiopathic</term>
</keywords>
<keywords scheme="MESH" qualifier="microbiologie" xml:lang="fr">
<term>Infections bactériennes</term>
</keywords>
<keywords scheme="MESH" qualifier="microbiology" xml:lang="en">
<term>Bacterial Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en">
<term>Bacterial Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr">
<term>Infections bactériennes</term>
</keywords>
<keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en">
<term>Vaccination</term>
</keywords>
<keywords scheme="MESH" qualifier="statistiques et données numériques" xml:lang="fr">
<term>Vaccination</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en">
<term>Purpura, Thrombocytopenic, Idiopathic</term>
</keywords>
<keywords scheme="MESH" qualifier="thérapie" xml:lang="fr">
<term>Purpura thrombopénique idiopathique</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr">
<term>Purpura thrombopénique idiopathique</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr">
<term>Anticorps monoclonaux d'origine murine</term>
<term>Facteurs immunologiques</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr">
<term>France</term>
<term>Infections bactériennes</term>
<term>Purpura thrombopénique idiopathique</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Cohort Studies</term>
<term>Drug Administration Schedule</term>
<term>Epidemiologic Research Design</term>
<term>Female</term>
<term>Humans</term>
<term>Logistic Models</term>
<term>Male</term>
<term>Practice Guidelines as Topic</term>
<term>Rituximab</term>
<term>Splenectomy</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Calendrier d'administration des médicaments</term>
<term>Femelle</term>
<term>Guides de bonnes pratiques cliniques comme sujet</term>
<term>Humains</term>
<term>Modèles logistiques</term>
<term>Mâle</term>
<term>Méthodologie en recherche épidémiologique</term>
<term>Rituximab</term>
<term>Splénectomie</term>
<term>Études de cohortes</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr">
<term>France</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">International guidelines on immune thrombocytopenia (ITP) management recommend vaccination against Streptococcus pneumoniae (S.p.), Haemophilus influenza b (Hib) and Neisseiria meningitidis (N.m.) before splenectomy. French guidelines also recommend these vaccinations before rituximab. The aim of this study was to assess the application of these recommendations. The French Adult ITP: a French pHarmacoepidemiological study (FAITH, n°ENCEPP 4574) is aimed at following in the French national health insurance system database (SNIIRAM) the cohort of all incident and persistent or chronic primary ITP adults treated in France. We assessed vaccine exposure in the 1,106 patients who entered the FAITH cohort between 2009 and 2011. Vaccination was said "recommended" if performed at least 2 weeks before rituximab or splenectomy accordingly with French guidelines. Among the 423 non-splenectomized patients exposed to rituximab, vaccination rates against S.p., Hib and N.m. were respectively 32.4%, 18.9%, and 3.8%. It was recommended in 12.8%, 6.6%, and 1.2% of the patients, respectively. Among the 178 splenectomized patients, vaccination rates were 70.2%, 47.0%, and 11.9%, respectively (recommended: 60.1%, 35.7%, and 9.5%). Among the splenectomized patients previously exposed to rituximab (n = 67), 53.3% of the vaccinations occurred during the semester following a rituximab infusion that is during the maximal B-cell depletion period. In multivariate analyses, a disease duration exceeding 3 months was the sole factor associated to recommended vaccination in rituximab-treated patients as well as in splenectomized patients. This study stresses the need of better and earlier vaccination of ITP patients.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">25557586</PMID>
<DateCompleted>
<Year>2015</Year>
<Month>06</Month>
<Day>01</Day>
</DateCompleted>
<DateRevised>
<Year>2015</Year>
<Month>11</Month>
<Day>19</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1096-8652</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>90</Volume>
<Issue>4</Issue>
<PubDate>
<Year>2015</Year>
<Month>Apr</Month>
</PubDate>
</JournalIssue>
<Title>American journal of hematology</Title>
<ISOAbbreviation>Am. J. Hematol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population-based study in France.</ArticleTitle>
<Pagination>
<MedlinePgn>301-5</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/ajh.23930</ELocationID>
<Abstract>
<AbstractText>International guidelines on immune thrombocytopenia (ITP) management recommend vaccination against Streptococcus pneumoniae (S.p.), Haemophilus influenza b (Hib) and Neisseiria meningitidis (N.m.) before splenectomy. French guidelines also recommend these vaccinations before rituximab. The aim of this study was to assess the application of these recommendations. The French Adult ITP: a French pHarmacoepidemiological study (FAITH, n°ENCEPP 4574) is aimed at following in the French national health insurance system database (SNIIRAM) the cohort of all incident and persistent or chronic primary ITP adults treated in France. We assessed vaccine exposure in the 1,106 patients who entered the FAITH cohort between 2009 and 2011. Vaccination was said "recommended" if performed at least 2 weeks before rituximab or splenectomy accordingly with French guidelines. Among the 423 non-splenectomized patients exposed to rituximab, vaccination rates against S.p., Hib and N.m. were respectively 32.4%, 18.9%, and 3.8%. It was recommended in 12.8%, 6.6%, and 1.2% of the patients, respectively. Among the 178 splenectomized patients, vaccination rates were 70.2%, 47.0%, and 11.9%, respectively (recommended: 60.1%, 35.7%, and 9.5%). Among the splenectomized patients previously exposed to rituximab (n = 67), 53.3% of the vaccinations occurred during the semester following a rituximab infusion that is during the maximal B-cell depletion period. In multivariate analyses, a disease duration exceeding 3 months was the sole factor associated to recommended vaccination in rituximab-treated patients as well as in splenectomized patients. This study stresses the need of better and earlier vaccination of ITP patients.</AbstractText>
<CopyrightInformation>© 2014 Wiley Periodicals, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Moulis</LastName>
<ForeName>Guillaume</ForeName>
<Initials>G</Initials>
<AffiliationInfo>
<Affiliation>Service De Médecine Interne, CHU De Toulouse, Toulouse, F-31000, France; Inserm, UMR1027, Toulouse, F-31000 France, Université De Toulouse III, UMR1027, Toulouse, F-31000, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Lapeyre-Mestre</LastName>
<ForeName>Maryse</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Mahévas</LastName>
<ForeName>Matthieu</ForeName>
<Initials>M</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Montastruc</LastName>
<ForeName>Jean-Louis</ForeName>
<Initials>JL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sailler</LastName>
<ForeName>Laurent</ForeName>
<Initials>L</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2015</Year>
<Month>03</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Am J Hematol</MedlineTA>
<NlmUniqueID>7610369</NlmUniqueID>
<ISSNLinking>0361-8609</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D058846">Antibodies, Monoclonal, Murine-Derived</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D001428">Bacterial Vaccines</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>4F4X42SYQ6</RegistryNumber>
<NameOfSubstance UI="D000069283">Rituximab</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="CommentIn">
<RefSource>Am J Hematol. 2015 Apr;90(4):271-2</RefSource>
<PMID Version="1">25677795</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D058846" MajorTopicYN="N">Antibodies, Monoclonal, Murine-Derived</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D001424" MajorTopicYN="N">Bacterial Infections</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D001428" MajorTopicYN="N">Bacterial Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015340" MajorTopicYN="N">Epidemiologic Research Design</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016553" MajorTopicYN="N">Purpura, Thrombocytopenic, Idiopathic</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000069283" MajorTopicYN="N">Rituximab</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D013156" MajorTopicYN="Y">Splenectomy</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName>
<QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2014</Year>
<Month>11</Month>
<Day>18</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised">
<Year>2014</Year>
<Month>12</Month>
<Day>17</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2014</Year>
<Month>12</Month>
<Day>22</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2015</Year>
<Month>1</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2015</Year>
<Month>1</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2015</Year>
<Month>6</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">25557586</ArticleId>
<ArticleId IdType="doi">10.1002/ajh.23930</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>France</li>
</country>
<region>
<li>Midi-Pyrénées</li>
<li>Occitanie (région administrative)</li>
</region>
</list>
<tree>
<noCountry>
<name sortKey="Lapeyre Mestre, Maryse" sort="Lapeyre Mestre, Maryse" uniqKey="Lapeyre Mestre M" first="Maryse" last="Lapeyre-Mestre">Maryse Lapeyre-Mestre</name>
<name sortKey="Mahevas, Matthieu" sort="Mahevas, Matthieu" uniqKey="Mahevas M" first="Matthieu" last="Mahévas">Matthieu Mahévas</name>
<name sortKey="Montastruc, Jean Louis" sort="Montastruc, Jean Louis" uniqKey="Montastruc J" first="Jean-Louis" last="Montastruc">Jean-Louis Montastruc</name>
<name sortKey="Sailler, Laurent" sort="Sailler, Laurent" uniqKey="Sailler L" first="Laurent" last="Sailler">Laurent Sailler</name>
</noCountry>
<country name="France">
<region name="Occitanie (région administrative)">
<name sortKey="Moulis, Guillaume" sort="Moulis, Guillaume" uniqKey="Moulis G" first="Guillaume" last="Moulis">Guillaume Moulis</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000191 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000191 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    GrippeFranceV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:25557586
   |texte=   Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population-based study in France.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:25557586" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a GrippeFranceV1 

Wicri

This area was generated with Dilib version V0.6.35.
Data generation: Sun Aug 9 07:31:43 2020. Site generation: Thu Mar 25 22:05:26 2021